相关实验视频

Updated: Jun 12, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

质子抑制剂降低了接受capecitabine治疗的患者的生存结果:元分析

Dina Mohyeldeen^1,2, Waleed Arafat¹

¹Oncology Department, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt.

Ecancermedicalscience

|June 10, 2025

概括

质子抑制剂 (PPI) 可能会降低capecitabine患者的手脚综合征,但会显著恶化生存结果,特别是无复发生存. 需要进一步的研究来澄清PPI和capecitabine的相互作用.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床研究临床研究

背景情况:

质子抑制剂 (PPI) 是常见的药物,其与capecitabine化疗的相互作用概况尚不清楚.
现有的文献提出了关于同时使用PPI和capecitabine的风险和益处的相互矛盾的数据.

研究的目的:

评估PPI对接受capecitabine治疗的患者生存结果的影响.
评估PPI对手脚综合征 (HFS) 在接受capecitabine治疗的患者发病率的影响.

主要方法:

一项对17项发表到2022年10月的研究的元分析,来源于PubMed,Medline和Cochrane数据库.
使用Revman Ver.进行的统计分析. 5.3 评估治疗疗效,药理动力学和HFS发生率.
包括大约3万名患者的数据来评估生存方面.

主要成果:

使用PPI与HFS发病率显著降低有关 (RR 0.77;95% CI:0.70-0.85;p < 0.00001).
相反,PPI使用与多个指标的生存率降低相关,特别是无复发生存率 (HR1.75;95% CI:1.21-2.53;p = 0.003).
在使用PPI与capecitabine的患者中,生存结果显著恶化,特别是在新辅助和辅助设置中.

结论:

虽然PPI可以减轻capecitabine治疗中的HFS,但它们的使用与较差的生存结果有关.
这些发现表明,PPI对capecitabine治疗疗效的潜在有害影响,特别是在长期存活方面.
需要进一步研究以阐明PPI和capecitabine之间的复杂相互作用,指导临床实践.

关键词:

卡佩西塔宾 (capecitabine) 是一种药物.手脚综合征 - 手脚综合征欧梅普拉 (omeprazole) 是一种药物.总体存活率总体存活率没有进展的生存率.质子抑制剂的使用没有复发的生存率.

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...